deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00926107

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.

Sponsor: Hellenic Cooperative Oncology Group

Conditions Ovarian Cancer
Interventions Temsirolimus
Updated 10 times since 2017 Last updated: Nov 9, 2011 Started: Jun 30, 2009 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment

Other terminated trials from Hellenic Cooperative Oncology Group

More terminations from Hellenic Cooperative Oncology Group

Other Ovarian Cancer trials with similar outcome

Browse all Ovarian Cancer trials

A PHASE2 clinical study on Ovarian Cancer, this trial is terminated or withdrawn. The trial is conducted by Hellenic Cooperative Oncology Group and has accumulated 10 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshotTerminated~Aug 2017 – ~May 2018 · 9 months · monthly snapshotTerminated~May 2018 – ~Jun 2018 · 31 days · monthly snapshotTerminated~Jun 2018 – ~Nov 2020 · 29 months · monthly snapshotTerminated~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 5 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Nov 2020 [monthly]

    Terminated PHASE2

  3. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE2

    First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hellenic Cooperative Oncology Group
Data source: Hellenic Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations